On June 9, authorities approved Minjubiju (tapacitamab), an orphan drug used to treat diffuse large B-cell lymphoma.
Diffuse large B-cell lymphoma (DLBL) is one of the most common lymphomas and is characterized by rapid progression.
The Ministry of Food and Drug Safety (Minister Oh Yoo-kyung) has approved this drug for use in combination with lenalidomide in adult patients with relapsed or refractory large B-cell lymphoma who are not suitable for transplantation autologous hematopoietic stem cells and who have failed one or more previous therapies. , and later stated that this drug was used as monotherapy.
‘Minjubiju (tapacitamab)’ binds to CD19, a surface antigen protein of B cells, and causes direct apoptosis, antibody-dependent phagocytosis, and antibody-mediated cell cytotoxicity, leading to B cell depletion, leading to B -large spread. cell lymphoma, providing new treatment opportunities. CD19 is a cell surface antigen protein specific for normal and malignant B lymphocytes.
↑The mechanism of action of minijubiju
For information, this drug is an immunoglobulin (IgG) subtype monoclonal antibody drug that targets CD19, a cell surface antigen protein on the surface of B cell lymphocytes.
The Food and Drug Safety Administration intends to do its best to promptly supply treatments whose safety and efficacy have been sufficiently established based on regulatory science. Reporter Kang Kyung-nam
